Byondis
Patrick Beusker is an experienced professional in the field of medicinal and protein chemistry, currently serving as the Director of Medicinal & Protein Chemistry at Byondis since November 2019. Prior to this role, Patrick held the position of Director of Medicinal & Protein Chemistry and Director of Antibody-Drug Conjugates at Synthon from June 2011 to October 2019. Patrick's career also includes co-founding Syntarga B.V. and serving as its Chief Scientific Officer from December 2001 to June 2011. Academically, Patrick completed a Ph.D. in Organic Chemistry and an M.Sc. in Chemistry at Radboud University between 1992 and 2001.
This person is not in any teams
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.